Jasvinder Singh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8849155/publications.pdf

Version: 2024-02-01

672 124,650 107 336
papers citations h-index g-index

710 710 710 147407 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Global, regional, and national prevalence of overweight and obesity in children and adults during $1980 \hat{a} \in (2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 766-781.$	6.3	9,122
2	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	6.3	7,061
3	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	6.3	6,376
4	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 385, 117-171.	6.3	5,847
5	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	6.3	5,578
6	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 2017, 377, 13-27.	13.9	5,014
7	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
8	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
9	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
10	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565
11	Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	6.3	2,858
12	The Global Burden of Cancer 2013. JAMA Oncology, 2015, 1, 505.	3.4	2,269
13	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
14	The State of US Health, 1990-2010. JAMA - Journal of the American Medical Association, 2013, 310, 591.	3.8	2,070
15	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1-26.	2.9	1,880
16	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	6.3	1,879
17	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	6.3	1,612
18	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589

#	Article	IF	CITATIONS
19	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	6.3	1,544
20	2012 Update of the 2008 American College of Rheumatology recommendations for the use of diseaseâ€modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 625-639.	1.5	1,413
21	Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 389, 1885-1906.	6.3	1,281
22	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 2012, 64, 1431-1446.	1.5	1,268
23	Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 980-1004.	6.3	1,230
24	The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 17-30.	3.7	1,200
25	A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ, The, 2014, 349, g5630-g5630.	3.0	1,179
26	Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infectious Diseases, The, 2018, 18, 1191-1210.	4.6	1,084
27	Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine,the, 2020, 8, 585-596.	5.2	1,049
28	The State of US Health, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 319, 1444.	3.8	1,042
29	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 1-25.	1.5	890
30	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 245-266.	3.7	823
31	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	6.3	786
32	Total Knee Arthroplasty Volume, Utilization, and Outcomes Among Medicare Beneficiaries, 1991-2010. JAMA - Journal of the American Medical Association, 2012, 308, 1227.	3.8	772
33	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.5	754
34	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	6.3	740
35	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. Journal of Clinical Epidemiology, 2014, 67, 745-753.	2.4	625
36	Rates of Total Joint Replacement in the United States: Future Projections to 2020–2040 Using the National Inpatient Sample. Journal of Rheumatology, 2019, 46, 1134-1140.	1.0	615

#	Article	IF	Citations
37	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 957-979.	6.3	609
38	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care and Research, 2012, 64, 1447-1461.	1.5	598
39	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
40	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	6.3	571
41	2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1789-1798.	0.5	545
42	GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ, The, 2016, 353, i2089.	3.0	507
43	The Global Burden of Anemia. Hematology/Oncology Clinics of North America, 2016, 30, 247-308.	0.9	493
44	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet, The, 2015, 386, 258-265.	6.3	487
45	Adverse effects of biologics: a network meta-analysis and Cochrane overview. The Cochrane Library, 2016, 2016, CD008794.	1.5	481
46	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
47	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 924-939.	1.5	466
48	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	2.1	461
49	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care and Research, 2020, 72, 744-760.	1.5	420
50	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
51	2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2557-2568.	2.9	393
52	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	2.9	391
53	The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 42-54.	3.7	390
54	Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 376-393.	4.9	359

#	Article	IF	Citations
55	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 1108-1123.	2.9	339
56	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis and Rheumatology, 2019, 71, 5-32.	2.9	312
57	Child and Adolescent Health From 1990 to 2015. JAMA Pediatrics, 2017, 171, 573.	3.3	306
58	2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis and Rheumatology, 2020, 72, 879-895.	2.9	302
59	Anakinra for Rheumatoid Arthritis: A Systematic Review. Journal of Rheumatology, 2009, 36, 1118-1125.	1.0	291
60	Epidemiology of Knee and Hip Arthroplasty: A Systematic Review§. The Open Orthopaedics Journal, 2011, 5, 80-85.	0.1	280
61	Racial disparities in knee and hip total joint arthroplasty: an 18-year analysis of national medicare data. Annals of the Rheumatic Diseases, 2014, 73, 2107-2115.	0.5	279
62	Periprosthetic infections after total shoulder arthroplasty: a 33-year perspective. Journal of Shoulder and Elbow Surgery, 2012, 21, 1534-1541.	1.2	270
63	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care and Research, 2019, 71, 2-29.	1.5	264
64	The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. Journal of Allergy and Clinical Immunology, 2014, 134, 800-807.	1.5	257
65	The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infectious Diseases, The, 2018, 18, 261-284.	4.6	246
66	Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical Therapeutics, 2011, 33, 679-707.	1.1	241
67	GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. Journal of Clinical Epidemiology, 2016, 76, 89-98.	2.4	232
68	A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. Cmaj, 2009, 181, 787-796.	0.9	219
69	The Attributable Risk of Smoking on Surgical Complications. Annals of Surgery, 2011, 254, 914-920.	2.1	202
70	Risk factors for gout and prevention: a systematic review of the literature. Current Opinion in Rheumatology, 2011, 23, 192-202.	2.0	202
71	Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Annals of the Rheumatic Diseases, 2007, 67, 1310-1316.	0.5	199
72	The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncology, The, 2019, 20, 1211-1225.	5.1	199

#	Article	IF	Citations
73	The Impact of Gender, Age, and Preoperative Pain Severity on Pain After TKA. Clinical Orthopaedics and Related Research, 2008, 466, 2717-2723.	0.7	191
74	Global Mortality From Firearms, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 320, 792.	3.8	189
75	Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US. JAMA Internal Medicine, 2022, 182, 153.	2.6	182
76	Chondroitin for osteoarthritis. The Cochrane Library, 2016, 2016, CD005614.	1.5	178
77	Quality of care for gout in the US needs improvement. Arthritis and Rheumatism, 2007, 57, 822-829.	6.7	176
78	Biologics for rheumatoid arthritis: an overview of Cochrane reviews., 2009,, CD007848.		174
79	A Population-Based Study of Trends in the Use of Total Hip and Total Knee Arthroplasty, 1969-2008. Mayo Clinic Proceedings, 2010, 85, 898-904.	1.4	172
80	Smoking and Outcomes After Knee and Hip Arthroplasty: A Systematic Review. Journal of Rheumatology, 2011, 38, 1824-1834.	1.0	171
81	Development of classification and response criteria for rheumatic diseases. Arthritis and Rheumatism, 2006, 55, 348-352.	6.7	170
82	The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis and Cartilage, 2011, 19, 147-154.	0.6	162
83	Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. Nature, 2019, 574, 353-358.	13.7	161
84	Gout epidemiology and comorbidities. Seminars in Arthritis and Rheumatism, 2020, 50, S11-S16.	1.6	157
85	Revision surgery following total shoulder arthroplasty. Journal of Bone and Joint Surgery: British Volume, 2011, 93-B, 1513-1517.	3.4	152
86	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain, 2016, 157, 1836-1850.	2.0	152
87	Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis and Rheumatology, 2016, 68, 2328-2337.	2.9	150
88	Preferred roles in treatment decision making among patients with cancer: a pooled analysis of studies using the Control Preferences Scale. American Journal of Managed Care, 2010, 16, 688-96.	0.8	150
89	Outcome Domains for Studies of Acute and Chronic Gout. Journal of Rheumatology, 2009, 36, 2342-2345.	1.0	147
90	Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infectious Diseases, The, 2018, 18, 1329-1349.	4.6	144

#	Article	IF	CITATIONS
91	Accuracy of veterans administration databases for a diagnosis of rheumatoid arthritis. Arthritis and Rheumatism, 2004, 51, 952-957.	6.7	141
92	Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. British Journal of Dermatology, 2017, 176, 979-984.	1.4	141
93	Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review. Journal of Rheumatology, 2011, 38, 10-20.	1.0	138
94	Clinically important improvement thresholds for Harris Hip Score and its ability to predict revision risk after primary total hip arthroplasty. BMC Musculoskeletal Disorders, 2016, 17, 256.	0.8	134
95	Predictors of pain and use of pain medications following primary Total Hip Arthroplasty (THA): 5,707 THAs at 2-years and 3,289 THAs at 5-years. BMC Musculoskeletal Disorders, 2010, 11, 90.	0.8	131
96	Anakinra for rheumatoid arthritis. The Cochrane Library, 2009, , CD005121.	1.5	129
97	Medical and psychological comorbidity predicts poor pain outcomes after total knee arthroplasty. Rheumatology, 2013, 52, 916-923.	0.9	127
98	TNF-alpha inhibitors for ankylosing spondylitis. The Cochrane Library, 2015, , CD005468.	1.5	126
99	Systematic Review of Tocilizumab for Rheumatoid Arthritis: A New Biologic Agent Targeting the Interleukin-6 Receptor. Clinical Therapeutics, 2012, 34, 788-802.e3.	1.1	124
100	Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses. Journal of Rheumatology, 2014, 41, 194-205.	1.0	124
101	Opioid use by patients in an orthopedics spine clinic. Arthritis and Rheumatism, 2005, 52, 312-321.	6.7	123
102	Classification criteria in rheumatic diseases: A review of methodologic properties. Arthritis and Rheumatism, 2007, 57, 1119-1133.	6.7	122
103	2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis and Rheumatology, 2017, 69, 1538-1551.	2.9	121
104	Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 2021, 7, e001814.	1.8	121
105	Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Medicine, 2016, 14, 137.	2.3	120
106	Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. Journal of Rheumatology, 2015, 42, 1962-1970.	1.0	116
107	Age, gender, obesity, and depression are associated with patient-related pain and function outcome after revision total hip arthroplasty. Clinical Rheumatology, 2009, 28, 1419-1430.	1.0	115
108	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2016, 175, 69-79.	1.4	115

#	Article	IF	Citations
109	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	1.8	115
110	Smoking as a risk factor for shortâ€term outcomes following primary total hip and total knee replacement in veterans. Arthritis Care and Research, 2011, 63, 1365-1374.	1.5	113
111	Are There Modifiable Risk Factors for Hospital Readmission After Total Hip Arthroplasty in a US Healthcare System?. Clinical Orthopaedics and Related Research, 2015, 473, 3446-3455.	0.7	112
112	Newer Biological Agents in Rheumatoid Arthritis. Drugs, 2010, 70, 121-145.	4.9	111
113	Adverse Effects of Smoking on Postoperative Outcomes in Cancer Patients. Annals of Surgical Oncology, 2012, 19, 1430-1438.	0.7	111
114	Medication adherence among patients with gout: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2018, 47, 689-702.	1.6	108
115	Long term effects of intra-articular botulinum toxin a for refractory joint pain. Neurotoxicity Research, 2006, 9, 179-188.	1.3	102
116	Periprosthetic infections after shoulder hemiarthroplasty. Journal of Shoulder and Elbow Surgery, 2012, 21, 1304-1309.	1.2	101
117	Perceptions of disease and health-related quality of life among patients with gout. Rheumatology, 2008, 48, 582-586.	0.9	100
118	Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review. Journal of Rheumatology, 2010, 37, 234-245.	1.0	100
119	2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care and Research, 2017, 69, 1111-1124.	1.5	100
120	Total Knee Arthroplasty in Morbidly Obese Patients Treated With Bariatric Surgery. Journal of Arthroplasty, 2012, 27, 1696-1700.	1.5	98
121	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Annals of the Rheumatic Diseases, 2017, 76, 1870-1882.	0.5	98
122	2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Journal of Arthroplasty, 2017, 32, 2628-2638.	1.5	97
123	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. Journal of Rheumatology, 2019, 46, 1021-1027.	1.0	97
124	Challenges With Health-related Quality of Life Assessment in Arthroplasty Patients: Problems and Solutions. Journal of the American Academy of Orthopaedic Surgeons, The, 2010, 18, 73-82.	1.1	97
125	Spondyloarthritis Is Associated with Poor Function and Physical Health-Related Quality of Life. Journal of Rheumatology, 2009, 36, 1012-1020.	1.0	96
126	Time trends in total ankle arthroplasty in the USA: a study of the National Inpatient Sample. Clinical Rheumatology, 2016, 35, 239-245.	1.0	96

#	Article	IF	CITATIONS
127	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2018, 178, e332-e341.	1.4	96
128	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. Lancet Rheumatology, The, 2022, 4, e33-e41.	2.2	96
129	Predictors of moderate–severe functional limitation after primary Total Knee Arthroplasty (TKA): 4701 TKAs at 2-years and 2935 TKAs at 5-years. Osteoarthritis and Cartilage, 2010, 18, 515-521.	0.6	95
130	Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). British Journal of Dermatology, 2014, 171, 1318-1325.	1.4	95
131	Bariatric Surgery Prior to Total Joint Arthroplasty May Not Provide Dramatic Improvements in Post-Arthroplasty Surgical Outcomes. Journal of Arthroplasty, 2014, 29, 1359-1364.	1.5	95
132	Current tobacco use is associated with higher rates of implant revision and deep infection after total hip or knee arthroplasty: a prospective cohort study. BMC Medicine, 2015, 13, 283.	2.3	94
133	Hospital volume and surgical outcomes after elective hip/knee arthroplasty: A riskâ€adjusted analysis of a large regional database. Arthritis and Rheumatism, 2011, 63, 2531-2539.	6.7	93
134	Health-Related Quality of Life, Functional Impairment, and Healthcare Utilization by Veterans: Veterans' Quality of Life Study. Journal of the American Geriatrics Society, 2005, 53, 108-113.	1.3	90
135	Developing a provisional definition of flare in patients with established gout. Arthritis and Rheumatism, 2012, 64, 1508-1517.	6.7	90
136	Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis. Arthritis Care and Research, 2014, 66, 990-997.	1.5	90
137	Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1813-1818.	0.5	90
138	Opportunities for improving medication use and monitoring in gout. Annals of the Rheumatic Diseases, 2009, 68, 1265-1270.	0.5	87
139	Are Gender, Comorbidity, and Obesity Risk Factors for Postoperative Periprosthetic Fractures After Primary Total Hip Arthroplasty?. Journal of Arthroplasty, 2013, 28, 126-131.e2.	1.5	87
140	Cardiac and thromboembolic complications and mortality in patients undergoing total hip and total knee arthroplasty. Annals of the Rheumatic Diseases, 2011, 70, 2082-2088.	0.5	86
141	Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome domains. Pain, 2018, 159, 673-683.	2.0	86
142	Mobile and Fixed-Bearing (All-Polyethylene Tibial Component) Total Knee Arthroplasty Designs. Journal of Bone and Joint Surgery - Series A, 2009, 91, 2104-2112.	1.4	85
143	Patient Burden of Axial Spondyloarthritis. Journal of Clinical Rheumatology, 2017, 23, 383-391.	0.5	85
144	Higher Body Mass Index Is Not Associated With Worse Pain Outcomes After Primary or Revision Total Knee Arthroplasty. Journal of Arthroplasty, 2011, 26, 366-374.e1.	1.5	84

#	Article	IF	Citations
145	Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10. Journal of Rheumatology, 2011, 38, 1452-1457.	1.0	84
146	Periprosthetic Fractures Associated with Primary Total Shoulder Arthroplasty and Primary Humeral Head Replacement. Journal of Bone and Joint Surgery - Series A, 2012, 94, 1777-1785.	1.4	84
147	Racial and Gender Disparities Among Patients with Gout. Current Rheumatology Reports, 2013, 15, 307.	2.1	84
148	Patient-centered interventions to improve medication management and adherence: A qualitative review of research findings. Patient Education and Counseling, 2014, 97, 310-326.	1.0	84
149	Remembering the forgotten non-communicable diseases. BMC Medicine, 2014, 12, 200.	2.3	82
150	Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. American Journal of Managed Care, 2008, 14, 234-54.	0.8	82
151	Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990–2013: findings from the Global Burden of Disease Study 2013. Annals of the Rheumatic Diseases, 2017, 76, 1365-1373.	0.5	81
152	How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0. Journal of Rheumatology, 2014, 41, 1025-1030.	1.0	78
153	Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Annals of the Rheumatic Diseases, 2009, 68, 1800-1804.	0.5	77
154	Racial/Ethnic Disparity in Rates and Outcomes of Total Joint Arthroplasty. Current Rheumatology Reports, 2016, 18, 20.	2.1	77
155	GRADE guidelines: 22. The GRADE approach for tests and strategies—from test accuracy to patient-important outcomes and recommendations. Journal of Clinical Epidemiology, 2019, 111, 69-82.	2.4	76
156	Predictors of use of pain medications for persistent knee pain after primary Total Knee Arthroplasty: a cohort study using an institutional joint registry. Arthritis Research and Therapy, 2012, 14, R248.	1.6	75
157	Utilization due to chronic obstructive pulmonary disease and its predictors: a study using the U.S. National Emergency Department Sample (NEDS). Respiratory Research, 2016, 17, 1.	1.4	73
158	Gout, Hyperuricemia, and Crystalâ€Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care and Research, 2019, 71, 427-434.	1.5	73
159	Predictors of Activity Limitation and Dependence on Walking Aids After Primary Total Hip Arthroplasty. Journal of the American Geriatrics Society, 2010, 58, 2387-2393.	1.3	72
160	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. Annals of the Rheumatic Diseases, 2019, 78, 1592-1600.	0.5	72
161	Evaluation of an Instrument Assessing Influence of Gout on Health-Related Quality of Life. Journal of Rheumatology, 2008, 35, 2406-2414.	1.0	71
162	Pessimistic explanatory style. Journal of Bone and Joint Surgery: British Volume, 2010, 92-B, 799-806.	3.4	69

#	Article	IF	CITATIONS
163	Efficacy of Intraâ€Articular Botulinum Toxin Type A in Painful Knee Osteoarthritis: A Pilot Study. PM and R, 2010, 2, 268-276.	0.9	69
164	Early Postoperative Mortality Following Joint Arthroplasty: A Systematic Review. Journal of Rheumatology, 2011, 38, 1507-1513.	1.0	69
165	Reliability and Clinically Important Improvement Thresholds for Osteoarthritis Pain and Function Scales: A Multicenter Study. Journal of Rheumatology, 2014, 41, 509-515.	1.0	69
166	Brief Report: Validation of a Definition of Flare in Patients With Established Gout. Arthritis and Rheumatology, 2018, 70, 462-467.	2.9	68
167	Development of gellan gum containing formulations for transdermal drug delivery: Component evaluation and controlled drug release using temperature responsive nanogels. International Journal of Pharmaceutics, 2016, 509, 465-476.	2.6	67
168	Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Translational Research, 2009, 153, 205-216.	2.2	66
169	Predictors of periprosthetic fracture after total knee replacement. Monthly Notices of the Royal Astronomical Society: Letters, 2013, 84, 170-177.	1.2	66
170	Trends in and disparities for acute myocardial infarction: an analysis of Medicare claims data from 1992 to 2010. BMC Medicine, 2014, 12, 190.	2.3	66
171	A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. Annals of the Rheumatic Diseases, 2008, 67, 888-891.	0.5	65
172	Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Research and Therapy, 2011, 13, R155.	1.6	65
173	Time Trends in the Characteristics of Patients Undergoing Primary Total Knee Arthroplasty. Arthritis Care and Research, 2014, 66, 897-906.	1.5	65
174	Depression in primary TKA and higher medical comorbidities in revision TKA are associated with suboptimal subjective improvement in knee function. BMC Musculoskeletal Disorders, 2014, 15, 127.	0.8	65
175	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1014-1020.	1.0	65
176	Immunohistochemistry of normal human knee synovium: a quantitative study. Annals of the Rheumatic Diseases, 2004, 63, 785-790.	0.5	64
177	Health-related quality of life predicts future health care utilization and mortality in veterans with self-reported physician-diagnosed arthritis: The veterans arthritis quality of life study. Seminars in Arthritis and Rheumatism, 2005, 34, 755-765.	1.6	64
178	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain, 2020, 161, 2446-2461.	2.0	64
179	Cardiac magnetic resonance imaging abnormalities in systemic lupus erythematosus: a preliminary report. Lupus, 2005, 14, 137-144.	0.8	63
180	Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Annals of the Rheumatic Diseases, 2016, 75, 341-347.	0.5	63

#	Article	IF	CITATIONS
181	Burden of cardiovascular diseases in the Eastern Mediterranean Region, 1990–2015: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 137-149.	1.0	63
182	Surgery for Shoulder Osteoarthritis: A Cochrane Systematic Review. Journal of Rheumatology, 2011, 38, 598-605.	1.0	62
183	GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale. Journal of Clinical Epidemiology, 2017, 90, 59-67.	2.4	62
184	Intra-articular Botulinum Toxin Type A: A new approach to treat arthritis joint pain. Toxicon, 2009, 54, 658-667.	0.8	61
185	Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales. Health and Quality of Life Outcomes, 2014, 12, 187.	1.0	61
186	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	1.0	61
187	Accuracy of the diagnoses of spondylarthritides in veterans affairs medical center databases. Arthritis and Rheumatism, 2007, 57, 648-655.	6.7	60
188	Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Research and Therapy, 2014, 16, R82.	1.6	60
189	Accuracy of VA databases for diagnoses of knee replacement and hip replacement. Osteoarthritis and Cartilage, 2010, 18, 1639-1642.	0.6	59
190	Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials. Journal of Rheumatology, 2012, 39, 1450-1457.	1.0	59
191	Biological pathways, candidate genes, and molecular markers associated with quality-of-life domains: an update. Quality of Life Research, 2014, 23, 1997-2013.	1.5	59
192	Quality of life and quality of care for patients with gout. Current Rheumatology Reports, 2009, 11, 154-160.	2.1	58
193	Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial. Journal of Rheumatology, 2010, 37, 2377-2386.	1.0	58
194	The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Research and Therapy, 2014, 16, R132.	1.6	57
195	Patient race and surgical outcomes after total knee arthroplasty: An analysis of a large regional database. Arthritis Care and Research, 2013, 65, 414-420.	1.5	55
196	Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. BMC Cardiovascular Disorders, 2017, 17, 76.	0.7	55
197	Ninety-day Mortality in Patients Undergoing Elective Total Hip or Total Knee Arthroplasty. Journal of Arthroplasty, 2012, 27, 1417-1422.e1.	1.5	54
198	Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Medical Journal, 2010, 128, 309-310.	0.4	54

#	Article	IF	Citations
199	Progress in Measurement Instruments for Acute and Chronic Gout Studies. Journal of Rheumatology, 2009, 36, 2346-2355.	1.0	53
200	Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Crossâ€Sectional Study of US Veterans. Arthritis Care and Research, 2017, 69, 1400-1406.	1.5	53
201	Diabetes: A Risk Factor for Poor Functional Outcome after Total Knee Arthroplasty. PLoS ONE, 2013, 8, e78991.	1.1	53
202	Challenges with health-related quality of life assessment in arthroplasty patients: problems and solutions. Journal of the American Academy of Orthopaedic Surgeons, The, 2010, 18, 72-82.	1.1	53
203	Abatacept for rheumatoid arthritis. The Cochrane Library, 2009, , CD007277.	1.5	52
204	Risk factors for revision surgery after humeral head replacement: 1,431 shoulders over 3 decades. Journal of Shoulder and Elbow Surgery, 2012, 21, 1039-1044.	1.2	52
205	Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: A 13-year study of time trends. BMC Musculoskeletal Disorders, 2014, 15, 441.	0.8	52
206	Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Research and Therapy, 2015, 17, 120.	1.6	52
207	Tocilizumab for rheumatoid arthritis. , 2010, , CD008331.		51
208	Predictors of Moderate-Severe Functional Limitation 2 and 5 Years After Revision Total Knee Arthroplasty. Journal of Arthroplasty, 2010, 25, 1091-1095.e4.	1.5	51
209	Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy, 2013, 5, 265-299.	1.0	51
210	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. The Cochrane Library, 2016, 2016, CD012183.	1.5	51
211	The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1899-1911.	1.5	51
212	Gout disease-specific quality of life and the association with gout characteristics. Patient Related Outcome Measures, 2010, 2010, 1.	0.7	50
213	Rheumatoid Arthritis is Associated With Higher Ninetyâ€Day Hospital Readmission Rates Compared to Osteoarthritis After Hip or Knee Arthroplasty: A Cohort Study. Arthritis Care and Research, 2015, 67, 718-724.	1.5	50
214	Burden of obesity in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 165-176.	1.0	50
215	Ninety day mortality and its predictors after primary shoulder arthroplasty: an analysis of 4,019 patients from 1976-2008. BMC Musculoskeletal Disorders, 2011, 12, 231.	0.8	49
216	Sex and Surgical Outcomes and Mortality After Primary Total Knee Arthroplasty: A Riskâ€Adjusted Analysis. Arthritis Care and Research, 2013, 65, 1095-1102.	1.5	49

#	Article	IF	CITATIONS
217	The Establishment of the GENEQOL Consortium to Investigate the Genetic Disposition of Patient-Reported Quality-of-Life Outcomes. Twin Research and Human Genetics, 2009, 12, 301-311.	0.3	48
218	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care and Research, 2016, 68, 667-672.	1.5	48
219	GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence. Journal of Clinical Epidemiology, 2017, 90, 76-83.	2.4	48
220	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. The Cochrane Library, 2017, 5, CD012657.	1.5	47
221	Use of breath carbon monoxide measurements to assess erythrocyte survival in subjects with chronic diseases. American Journal of Hematology, 2006, 81, 432-438.	2.0	46
222	Goutâ€Related Health Care Utilization in US Emergency Departments, 2006 Through 2008. Arthritis Care and Research, 2013, 65, 571-577.	1.5	46
223	GRADE equity guidelines 2: considering health equity in GRADE guideline development: equity extension of the guideline development checklist. Journal of Clinical Epidemiology, 2017, 90, 68-75.	2.4	46
224	Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 158-164.	1.0	46
225	Veterans Affairs databases are accurate for gout-related health care utilization: a validation study. Arthritis Research and Therapy, 2013, 15, R224.	1.6	45
226	Challenges Faced by Patients in Gout Treatment. Journal of Clinical Rheumatology, 2014, 20, 172-174.	0.5	45
227	Increasing comorbidity is associated with worsening physical function and pain after primary total knee arthroplasty. BMC Musculoskeletal Disorders, 2016, 17, 421.	0.8	45
228	GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process. Journal of Clinical Epidemiology, 2017, 90, 84-91.	2.4	45
229	Leflunomide use during the first 33 months after food and drug administration approval: Experience with a national cohort of 3,325 patients. Arthritis and Rheumatism, 2003, 49, 745-751.	6.7	44
230	Golimumab for rheumatoid arthritis. The Cochrane Library, 2010, 2010, CD008341.	1.5	44
231	Health Care Utilization in Patients with Gout. Seminars in Arthritis and Rheumatism, 2011, 40, 501-511.	1.6	44
232	Comparison of Patient-Reported and Clinician-Assessed Outcomes Following Total Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2011, 93, e117.	1.4	44
233	Investigational drugs for hyperuricemia. Expert Opinion on Investigational Drugs, 2015, 24, 1013-1030.	1.9	44
234	Patient-centered priorities for improving medication management and adherence. Patient Education and Counseling, 2015, 98, 102-110.	1.0	44

#	Article	IF	Citations
235	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. The Cochrane Library, 2017, 2017, CD012591.	1.5	44
236	Surgery for shoulder osteoarthritis. The Cochrane Library, 2010, , CD008089.	1.5	43
237	Impaired response or insufficient dosage?—Examining the potential causes of "inadequate response―to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism, 2014, 44, 170-174.	1.6	43
238	Age-related differences in the use of total shoulder arthroplasty over time. Bone and Joint Journal, 2015, 97-B, 1385-1389.	1.9	43
239	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. Arthritis Care and Research, 2016, 68, 1579-1590.	1.5	43
240	The burden of mental disorders in the Eastern Mediterranean region, 1990–2015: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 25-37.	1.0	43
241	Examining Timeliness of Total Knee Replacement Among Patients with Knee Osteoarthritis in the U.S Journal of Bone and Joint Surgery - Series A, 2020, 102, 468-476.	1.4	43
242	Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Diabetes and Endocrinology,the, 2022, 10, 655-667.	5.5	43
243	National U.S. time-trends in opioid use disorder hospitalizations and associated healthcare utilization and mortality. PLoS ONE, 2020, 15, e0229174.	1.1	42
244	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). Patient, 2017, 10, 141-152.	1.1	41
245	Accuracy of Veterans Affairs databases for diagnoses of chronic diseases. Preventing Chronic Disease, 2009, 6, A126.	1.7	41
246	Patient understanding and satisfaction in informed consent for total knee arthroplasty: A randomized study. Arthritis Care and Research, 2011, 63, 1048-1054.	1.5	40
247	Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology, 2022, 61, SI143-SI150.	0.9	40
248	Toward a valid definition of gout flare: Results of consensus exercises using delphi methodology and cognitive mapping. Arthritis and Rheumatism, 2009, 61, 535-543.	6.7	39
249	Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. Journal of Rheumatology, 2015, 42, 2460-2464.	1.0	39
250	Assessment of a Satisfaction Measure for Use After Primary Total Joint Arthroplasty. Journal of Arthroplasty, 2020, 35, 1792-1799.e4.	1.5	39
251	Comorbidities in Patients with Crystal Diseases and Hyperuricemia. Rheumatic Disease Clinics of North America, 2014, 40, 251-278.	0.8	37
252	Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims. Arthritis Research and Therapy, 2016, 18, 209.	1.6	37

#	Article	IF	CITATIONS
253	Association of Race/Ethnicity With Hospital Discharge Disposition After Elective Total Knee Arthroplasty. JAMA Network Open, 2019, 2, e1914259.	2.8	37
254	Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. Hypertension, 2020, 75, 246-256.	1.3	37
255	Clinically Important Body Weight Gain Following Knee Arthroplasty: A Fiveâ€ Y ear Comparative Cohort Study. Arthritis Care and Research, 2013, 65, 669-677.	1.5	36
256	Achieving Consensus on Total Joint Replacement Trial Outcome Reporting Using the OMERACT Filter: Endorsement of the Final Core Domain Set for Total Hip and Total Knee Replacement Trials for Endstage Arthritis. Journal of Rheumatology, 2017, 44, 1723-1726.	1.0	36
257	Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data. Annals of the Rheumatic Diseases, 2017, 76, 72-78.	0.5	36
258	Cardiovascular Disease in Gout and theÂProtective Effect of Treatments Including Urate-Lowering Therapy. Drugs, 2019, 79, 531-541.	4.9	36
259	Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. American Journal of Managed Care, 2007, 13 Suppl 9, S237-51.	0.8	36
260	When gout goes to the heart: does gout equal a cardiovascular disease risk factor?. Annals of the Rheumatic Diseases, 2015, 74, 631-634.	0.5	35
261	Repeat Injections of Intra-Articular Botulinum Toxin A for the Treatment of Chronic Arthritis Joint Pain. Journal of Clinical Rheumatology, 2009, 15, 35-38.	0.5	34
262	The Influence of the Contralateral Knee Prior to Knee Arthroplasty on Post-Arthroplasty Function: The Multicenter Osteoarthritis Study. Journal of Bone and Joint Surgery - Series A, 2013, 95, 989-993.	1.4	34
263	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of "Truth― Content, Face, and Construct Validity. Journal of Rheumatology, 2014, 41, 1000-1004.	1.0	34
264	Does Hospital Volume Predict Outcomes and Complications After Total Shoulder Arthroplasty in the US?. Arthritis Care and Research, 2015, 67, 885-890.	1.5	34
265	Validity and sensitivity to change of three scales for the radiographic assessment of knee osteoarthritis using images from the Multicenter Osteoarthritis Study (MOST). Osteoarthritis and Cartilage, 2015, 23, 1491-1498.	0.6	33
266	Persisting Racial Disparities in Total Shoulder Arthroplasty Utilization and Outcomes. Journal of Racial and Ethnic Health Disparities, 2016, 3, 259-266.	1.8	33
267	When Patients Write the Guidelines: Patient Panel Recommendations for the Treatment of Rheumatoid Arthritis. Arthritis Care and Research, 2016, 68, 26-35.	1.5	33
268	Higher comorbidity, poor functional status and higher health care utilization in veterans with prevalent total knee arthroplasty or total hip arthroplasty. Clinical Rheumatology, 2009, 28, 1025-1033.	1.0	32
269	The relation between cancer patient treatment decisionâ€making roles and quality of life. Cancer, 2013, 119, 2342-2349.	2.0	32
270	Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies. Current Rheumatology Reports, 2016, 18, 61.	2.1	32

#	Article	IF	Citations
271	Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. Seminars in Arthritis and Rheumatism, 2018, 48, 293-301.	1.6	32
272	Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data. RMD Open, 2018, 4, e000712.	1.8	32
273	Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of U.S. Medicare population. BMC Nephrology, 2019, 20, 93.	0.8	32
274	Variation in Outcome Measures in Hip and Knee Arthroplasty Clinical Trials: A Proposed Approach to Achieving Consensus. Journal of Rheumatology, 2009, 36, 2050-2056.	1.0	31
275	Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology, 2011, 50, 1331-1336.	0.9	31
276	Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: A report of two cases. Joint Bone Spine, 2009, 76, 190-194.	0.8	30
277	Participation Following Knee Replacement: The MOST Cohort Study. Physical Therapy, 2013, 93, 1467-1474.	1.1	30
278	Patient-level improvements in pain and activities of daily living after total knee arthroplasty. Rheumatology, 2014, 53, 313-320.	0.9	30
279	Association of Early Postoperative Pain Trajectories With Longer-term Pain Outcome After Primary Total Knee Arthroplasty. JAMA Network Open, 2019, 2, e1915105.	2.8	30
280	COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. Lancet Rheumatology, The, 2022, 4, e237-e240.	2.2	30
281	Cardiopulmonary Complications After Primary Shoulder Arthroplasty: A Cohort Study. Seminars in Arthritis and Rheumatism, 2012, 41, 689-697.	1.6	29
282	Gout and dementia in the elderly: a cohort study of Medicare claims. BMC Geriatrics, 2018, 18, 281.	1.1	29
283	Can patients help with long-term total knee arthroplasty surveillance? Comparison of the American Knee Society Score self-report and surgeon assessment. Rheumatology, 2009, 48, 160-164.	0.9	28
284	Outcome Measures in Acute Gout: A Systematic Literature Review. Journal of Rheumatology, 2014, 41, 558-568.	1.0	28
285	Outcome Domains and Measures in Total Joint Replacement Clinical Trials: Can We Harmonize Them? An OMERACT Collaborative Initiative. Journal of Rheumatology, 2015, 42, 2496-2502.	1.0	28
286	Racial disparities in total ankle arthroplasty utilization and outcomes. Arthritis Research and Therapy, 2015, 17, 70.	1.6	28
287	Treatments for Lupus Nephritis: A Systematic Review and Network Metaanalysis. Journal of Rheumatology, 2016, 43, 1801-1815.	1.0	28
288	The burden of septic arthritis on the U.S. inpatient care: A national study. PLoS ONE, 2017, 12, e0182577.	1.1	28

#	Article	IF	Citations
289	Golimumab for Rheumatoid Arthritis: A Systematic Review. Journal of Rheumatology, 2010, 37, 1096-1104.	1.0	27
290	Summary of AHRQ's Comparative Effectiveness Review of Drug Therapy for Rheumatoid Arthritis (RA) in Adults – An Update. Journal of Managed Care Pharmacy, 2012, 18, 1-18.	2.2	27
291	Research Priorities in Gout: The Patient Perspective. Journal of Rheumatology, 2014, 41, 615-616.	1.0	27
292	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). The Cochrane Library, 2016, 2016, CD012437.	1.5	27
293	Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease. Mayo Clinic Proceedings, 2017, 92, 555-564.	1.4	27
294	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. Journal of Rheumatology, 2017, 44, 1551-1559.	1.0	27
295	Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study. Arthritis Research and Therapy, 2017, 19, 228.	1.6	27
296	Septic Arthritis in Emergency Departments in the <scp>US</scp> : A National Study of Health Care Utilization and Time Trends. Arthritis Care and Research, 2018, 70, 320-326.	1.5	27
297	Validation of the Hip Disability and Osteoarthritis Outcome Score and Knee Injury and Osteoarthritis Outcome Score Pain and Function Subscales for Use in Total Hip Replacement and Total Knee Replacement Clinical Trials. Journal of Arthroplasty, 2020, 35, 1200-1207.e4.	1.5	27
298	Patient Factors Predict Periprosthetic Fractures After Revision Total Hip Arthroplasty. Journal of Arthroplasty, 2012, 27, 1507-1512.	1.5	26
299	Predictors of pain medication use for arthroplasty pain after revision total knee arthroplasty. Rheumatology, 2014, 53, 1752-1758.	0.9	26
300	OMERACT Endorsement of Measures of Outcome for Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 569-573.	1.0	26
301	Muscle inflammation susceptibility: a prognostic index of recovery potential after hip arthroplasty?. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E670-E679.	1.8	26
302	Allopurinol and the risk of stroke in older adults receiving medicare. BMC Neurology, 2016, 16, 164.	0.8	26
303	Clinical Practice Guidelines: Incorporating Input From a Patient Panel. Arthritis Care and Research, 2017, 69, 1125-1130.	1.5	26
304	Medicaid or Medicare insurance payer status and household income are associated with outcomes after primary total hip arthroplasty. Clinical Rheumatology, 2018, 37, 2489-2496.	1.0	26
305	Assessment of outcome in clinical trials of gout a review of current measures. Rheumatology, 2007, 46, 1751-1756.	0.9	25
306	Predictors of doctorâ€rated and patientâ€rated gout severity: gout impact scales improve assessment. Journal of Evaluation in Clinical Practice, 2010, 16, 1244-1247.	0.9	25

#	Article	IF	Citations
307	Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adolopment. Health and Quality of Life Outcomes, 2017, 15, 183.	1.0	25
308	Health-related quality of life in veterans with prevalent total knee arthroplasty and total hip arthroplasty. Rheumatology, 2008, 47, 1826-1831.	0.9	24
309	Botulinum toxin therapy for osteoarticular pain: an evidence-based review. Therapeutic Advances in Musculoskeletal Disease, 2010, 2, 105-118.	1.2	24
310	Receipt of Pain Management Information Preoperatively Is Associated With Improved Functional Gain After Elective Total Joint Arthroplasty. Journal of Arthroplasty, 2017, 32, 1763-1768.	1.5	24
311	Management of Rheumatic Diseases During the COVID†19 Pandemic: A National Veterans Affairs Survey of Rheumatologists. Arthritis Care and Research, 2021, 73, 998-1003.	1.5	24
312	Health care utilization in patients with spondyloarthropathies. Rheumatology, 2008, 48, 272-276.	0.9	23
313	Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials. Journal of Rheumatology, 2011, 38, 1467-1470.	1.0	23
314	Botulinum Toxin for Shoulder Pain: A Cochrane Systematic Review. Journal of Rheumatology, 2011, 38, 409-418.	1.0	23
315	Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. Contemporary Clinical Trials, 2012, 33, 1211-1216.	0.8	23
316	Income and patient-reported outcomes (PROs) after primary total knee arthroplasty. BMC Medicine, 2013, 11, 62.	2.3	23
317	Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. Journal of Rheumatology, 2015, 42, 1616-1623.	1.0	23
318	Patient Endorsement of the Outcome Measures in Rheumatology (OMERACT) Total Joint Replacement (TJR) clinical trial draft core domain set. BMC Musculoskeletal Disorders, 2017, 18, 111.	0.8	23
319	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials, 2018, 19, 204.	0.7	23
320	Burden of lower respiratory infections in the Eastern Mediterranean Region between 1990 and 2015: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 97-108.	1.0	23
321	Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis. Arthritis Research and Therapy, 2018, 20, 167.	1.6	23
322	Factors associated with the orthopaedic surgeon's decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1905 patients. Osteoarthritis and Cartilage, 2018, 26, 1311-1318.	0.6	23
323	Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS Medicine, 2019, 16, e1002800.	3.9	23
324	Gout and the risk of Parkinson's disease in older adults: a study of U.S. Medicare data. BMC Neurology, 2019, 19, 4.	0.8	23

#	Article	IF	CITATIONS
325	Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction. Arthritis Care and Research, 2022, 74, 1649-1658.	1.5	23
326	Healthcare is a Team Sport: Stress, Resilience, and Correlates of Well-Being Among Health System Employees in a Crisis. Journal of Healthcare Management, 2021, 66, 304-322.	0.4	23
327	Gender and Ethnic Inequities in Gout Burden and Management. Rheumatic Disease Clinics of North America, 2020, 46, 693-703.	0.8	23
328	Botulinum toxin for shoulder pain. The Cochrane Library, 2010, , CD008271.	1.5	22
329	Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. Annals of the Rheumatic Diseases, 2011, 70, 1277-1281.	0.5	22
330	Patient-level clinically meaningful improvements in activities of daily living and pain after total hip arthroplasty: data from a large US institutional registry. Rheumatology, 2013, 52, 1109-1118.	0.9	22
331	An underlying diagnosis of osteonecrosis of bone is associated with worse outcomes than osteoarthritis after total hip arthroplasty. BMC Musculoskeletal Disorders, 2017, 18, 8.	0.8	22
332	Expert opinion on emerging urate-lowering therapies. Expert Opinion on Emerging Drugs, 2018, 23, 201-209.	1.0	22
333	Patients' perspectives of outcomes after total knee and total hip arthroplasty: a nominal group study. BMC Rheumatology, 2020, 4, 3.	0.6	22
334	Effect of comorbidity on quality of life of male veterans with prevalent primary total knee arthroplasty. Clinical Rheumatology, 2009, 28, 1083-1089.	1.0	21
335	Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities. Journal of Rheumatology, 2011, 38, 1458-1461.	1.0	21
336	Better Functional and Similar Pain Outcomes in Osteoarthritis Compared to Rheumatoid Arthritis After Primary Total Knee Arthroplasty: A Cohort Study. Arthritis Care and Research, 2013, 65, 1936-1941.	1.5	21
337	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. Journal of Rheumatology, 2015, 42, 2448-2459.	1.0	21
338	Depression and Anxiety following Coronary Artery Bypass Graft: Current Indian Scenario. Cardiology Research and Practice, 2016, 2016, 1-6.	0.5	21
339	Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study. Journal of Rheumatology, 2016, 43, 1581-1588.	1.0	21
340	Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. Arthritis Research and Therapy, 2020, 22, 86.	1.6	21
341	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care and Research, 2022, 74, 1399-1408.	1.5	21
342	Telemedicine in rheumatology care: A systematic review. Seminars in Arthritis and Rheumatism, 2022, 56, 152045.	1.6	21

#	Article	IF	Citations
343	Treatment Guidelines in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2022, 48, 679-689.	0.8	21
344	Are outcomes after total knee arthroplasty worsening over time? A time-trends study of activity limitation and pain outcomes. BMC Musculoskeletal Disorders, 2014, 15, 440.	0.8	20
345	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. Journal of Rheumatology, 2014, 41, 994-999.	1.0	20
346	Does Clinically Important Change in Function After Knee Replacement Guarantee Good Absolute Function? The Multicenter Osteoarthritis Study. Journal of Rheumatology, 2014, 41, 60-64.	1.0	20
347	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. Journal of Rheumatology, 2015, 42, 1947-1953.	1.0	20
348	Gout: will the "King of Diseases―be the first rheumatic disease to be cured?. BMC Medicine, 2016, 14, 180.	2.3	20
349	General Assembly, Prevention, Host Related General: Proceedings of International Consensus on Orthopedic Infections. Journal of Arthroplasty, 2019, 34, S13-S35.	1.5	20
350	Use of botulinum toxin in musculoskeletal pain. F1000Research, 2013, 2, 52.	0.8	20
351	Spondyloarthropathy: An Independent Risk Factor for Kidney Stones. Journal of Endourology, 2006, 20, 542-546.	1.1	19
352	Effect of resistance exercise on bone mineral density in premenopausal women. Joint Bone Spine, 2009, 76, 273-280.	0.8	19
353	Gout in the Hmong in the United States. Journal of Clinical Rheumatology, 2010, 16, 262-266.	0.5	19
354	Pegloticase for chronic gout. The Cochrane Library, 2010, , CD008335.	1.5	19
355	Update of Strategies to Translate Evidence from Cochrane Musculoskeletal Group Systematic Reviews for Use by Various Audiences. Journal of Rheumatology, 2014, 41, 206-215.	1.0	19
356	Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure. Annals of the Rheumatic Diseases, 2017, 76, 133-139.	0.5	19
357	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism, 2017, 46, 699-708.	1.6	19
358	Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout. Arthritis Care and Research, 2018, 70, 659-671.	1.5	19
359	Tai Chi for rheumatoid arthritis. The Cochrane Library, 2019, 9, CD004849.	1.5	19
360	Hospitalized Infections in Lupus: A Nationwide Study of Types of Infections, Time Trends, Health Care Utilization, and Inâ€Hospital Mortality. Arthritis and Rheumatology, 2021, 73, 617-630.	2.9	19

#	Article	IF	Citations
361	Biologicals for rheumatoid arthritis. BMJ: British Medical Journal, 2011, 343, d4027-d4027.	2.4	18
362	A systematic review of validated methods for identifying orthopedic implant removal and revision using administrative data. Pharmacoepidemiology and Drug Safety, 2012, 21, 265-273.	0.9	18
363	Updating the OMERACT Filter: Discrimination and Feasibility. Journal of Rheumatology, 2014, 41, 1005-1010.	1.0	18
364	An Internet Survey of Common Treatments Used by Patients With Gout Including Cherry Extract and Juice and Other Dietary Supplements. Journal of Clinical Rheumatology, 2015, 21, 225-226.	0.5	18
365	A cross-sectional internet-based patient survey of the management strategies for gout. BMC Complementary and Alternative Medicine, 2016, 16, 90.	3.7	18
366	Cytokine and neuropeptide levels are associated with pain relief in patients with chronically painful total knee arthroplasty: a pilot study. BMC Musculoskeletal Disorders, 2017, 18, 17.	0.8	18
367	Consensus on draft OMERACT core domains for clinical trials of Total Joint Replacement outcome by orthopaedic surgeons: a report from the International consensus on outcome measures in TJR trials (I-COMiTT) group. BMC Musculoskeletal Disorders, 2017, 18, 45.	0.8	18
368	Comparative effectiveness of allopurinol and febuxostat for the risk of atrial fibrillation in the elderly: a propensity-matched analysis of Medicare claims data. European Heart Journal, 2019, 40, 3046-3054.	1.0	18
369	Socioeconomic status and healthcare access are associated with healthcare utilization after knee arthroplasty: A U.S. national cohort study. Joint Bone Spine, 2020, 87, 157-162.	0.8	18
370	Diagnostic accuracy of salivary gland ultrasound in Sjögren's syndrome: A systematic review and meta-analysis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097356.	1.2	18
371	Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatology, The, 2022, 4, e53-e60.	2.2	18
372	The effects of intra-articular botulinum toxin on sacroiliac, cervical/lumbar facet and sterno-clavicular joint pain and C-2 root and lumbar disc pain: a case series of 11 patients. The Pain Clinic, 2007, 19, 27-32.	0.1	17
373	Absence of histologic evidence of synovitis in patients with Gulf War veterans' illness with joint pain. Arthritis and Rheumatism, 2007, 57, 1316-1323.	6.7	17
374	Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?. Journal of Rheumatology, 2011, 38, 1462-1466.	1.0	17
375	Validation of Administrative Codes for Calcium Pyrophosphate Deposition. Journal of Clinical Rheumatology, 2015, 21, 189-192.	0.5	17
376	Mapping Perceptions of Lupus Medication Decisionâ€Making Facilitators: The Importance of Patient Context. Arthritis Care and Research, 2016, 68, 1787-1794.	1.5	17
377	Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis. Systematic Reviews, 2016, 5, 155.	2.5	17
378	Adolescent health in the Eastern Mediterranean Region: findings from the global burden of disease 2015 study. International Journal of Public Health, 2018, 63, 79-96.	1.0	17

#	Article	IF	CITATIONS
379	Defining ranges for certainty ratings of diagnostic accuracy: a GRADE concept paper. Journal of Clinical Epidemiology, 2020, 117, 138-148.	2.4	17
380	Time Trends in Opioid Use Disorder Hospitalizations in Gout, Rheumatoid Arthritis, Fibromyalgia, Osteoarthritis, and Low Back Pain. Journal of Rheumatology, 2021, 48, 775-784.	1.0	17
381	Association of peptic ulcer disease and pulmonary disease with risk of periprosthetic fracture after primary total knee arthroplasty. Arthritis Care and Research, 2011, 63, 1471-1476.	1.5	16
382	Ipsilateral lower extremity joint involvement increases the risk of poor pain and function outcomes after hip or knee arthroplasty. BMC Medicine, 2013, 11, 144.	2.3	16
383	Clinically important body weight gain following total hip arthroplasty: a cohort study with 5-year follow-up. Osteoarthritis and Cartilage, 2013, 21, 35-43.	0.6	16
384	Patients with osteoarthritis and avascular necrosis have better functional outcomes and those with avascular necrosis worse pain outcomes compared to rheumatoid arthritis after primary hip arthroplasty: a cohort study. BMC Medicine, 2013, 11, 210.	2.3	16
385	Application of the OMERACT Filter to Measures of Core Outcome Domains in Recent Clinical Studies of Acute Gout. Journal of Rheumatology, 2014, 41, 574-580.	1.0	16
386	Sex differences in characteristics, utilization, and outcomes of patient undergoing total elbow arthroplasty: a study of the US nationwide inpatient sample. Clinical Rheumatology, 2016, 35, 723-731.	1.0	16
387	Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Annals of the Rheumatic Diseases, 2017, 76, 1669-1678.	0.5	16
388	Patients and surgeons provide endorsement of core domains for total joint replacement clinical trials. Arthritis Research and Therapy, 2017, 19, 267.	1.6	16
389	Untangling the complex relationships between incident gout risk, serum urate, and its comorbidities. Arthritis Research and Therapy, 2018, 20, 90.	1.6	16
390	Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. Drugs and Aging, 2019, 36, 493-510.	1.3	16
391	Race, Discharge Disposition, and Readmissions After Elective Hip Replacement: Analysis of a Large Regional Dataset. Health Equity, 2019, 3, 628-636.	0.8	16
392	Misconceived expectations: Patient reflections on the total knee replacement journey. Musculoskeletal Care, 2020, 18, 415-424.	0.6	16
393	Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis — Past, Present, and Future. New England Journal of Medicine, 2022, 386, 387-389.	13.9	16
394	Assessment of the Methodologic Quality of Medical and Surgical Clinical Trials in Patients with Arthroplasty. Journal of Rheumatology, 2009, 36, 2642-2654.	1.0	15
395	Operative diagnosis for revision total hip arthroplasty is associated with patient-reported outcomes (PROs). BMC Musculoskeletal Disorders, 2013, 14, 210.	0.8	15
396	Medical Comorbidity is Associated with Persistent Index Hip Pain after Total Hip Arthroplasty. Pain Medicine, 2013, 14, 1222-1229.	0.9	15

#	Article	IF	CITATIONS
397	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. Journal of Rheumatology, 2015, 42, 1971-1975.	1.0	15
398	Emergency Department and Inpatient Healthcare utilization due to Hypertension. BMC Health Services Research, 2016, 16, 303.	0.9	15
399	Gout Selfâ€Management in African American Veterans: A Qualitative Exploration of Challenges and Solutions From Patients' Perspectives. Arthritis Care and Research, 2017, 69, 1724-1732.	1.5	15
400	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1889-1893.	1.0	15
401	Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. Journal of Rheumatology, 2018, 45, 419-424.	1.0	15
402	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. Journal of Rheumatology, 2020, 47, 1565-1574.	1.0	15
403	Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2096612.	1.2	15
404	Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy. The Cochrane Library, 2020, 2020, CD012879.	1.5	15
405	Dual-energy computed tomography <i>vs</i> ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy. Rheumatology, 2021, 60, 4861-4867.	0.9	15
406	Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110166.	1.2	15
407	Trial sample size, but not trial quality, is associated with positive study outcome. Journal of Clinical Epidemiology, 2010, 63, 154-162.	2.4	14
408	Applying science in practice: the optimization of biological therapy in rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, 220.	1.6	14
409	Using tablet computers compared to interactive voice response to improve subject recruitment in osteoporosis pragmatic clinical trials: feasibility, satisfaction, and sample size. Patient Preference and Adherence, 2013, 7, 517.	0.8	14
410	A47: Progress Report on the Development of New Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies. Arthritis and Rheumatology, 2014, 66, S70-S71.	2.9	14
411	Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers. Journal of Rheumatology, 2014, 41, 1016-1024.	1.0	14
412	Racial differences in health-related quality of life and functional ability in patients with gout. Rheumatology, 2017, 56, 103-112.	0.9	14
413	The Association of Vibratory Perception and Muscle Strength With the Incidence and Worsening of Knee Instability: The Multicenter Osteoarthritis Study. Arthritis and Rheumatology, 2017, 69, 94-102.	2.9	14
414	Is Rheumatoid Arthritis a Cardiovascular Riskâ€Equivalent to Diabetes Mellitus?. Arthritis Care and Research, 2018, 70, 1694-1699.	1.5	14

#	Article	IF	Citations
415	Gout and the Risk of Incident Obstructive Sleep Apnea in Adults 65 Years or Older: An Observational Study. Journal of Clinical Sleep Medicine, 2018, 14, 1521-1527.	1.4	14
416	Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. Therapeutic Advances in Musculoskeletal Disease, 2018, 10, 235-252.	1.2	14
417	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. Journal of Rheumatology, 2019, 46, 1409-1414.	1.0	14
418	Insurance Payer Type and Patient Income Are Associated with Outcomes after Total Shoulder Arthroplasty. Journal of Rheumatology, 2020, 47, 589-596.	1.0	14
419	Stem cells and other innovative intra-articular therapies for osteoarthritis: what does the future hold?. BMC Medicine, 2012, 10, 44.	2.3	13
420	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. Arthritis Research and Therapy, 2015, 17, 136.	1.6	13
421	Minorities with lupus nephritis and medications: a study of facilitators to medication decision-making. Arthritis Research and Therapy, 2015, 17, 367.	1.6	13
422	Trends in HIV/AIDS morbidity and mortality in Eastern Mediterranean countries, 1990–2015: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 123-136.	1.0	13
423	Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adolopment of the 2015 American College of Rheumatology guidelines. Clinical Rheumatology, 2018, 37, 2947-2959.	1.0	13
424	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Seminars in Arthritis and Rheumatism, 2021, 51, 593-600.	1.6	13
425	Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naà ve patients. Journal of Rheumatology, 2004, 31, 1281-5.	1.0	13
426	Advances in gout: some answers, more questions. Arthritis Research and Therapy, 2010, 12, 136.	1.6	12
427	Gout-related inpatient utilization: a study of predictors of outcomes and time trends. Arthritis Research and Therapy, 2016, 18, 57.	1.6	12
428	Validation of the Mayo Hip Score: construct validity, reliability and responsiveness to change. BMC Musculoskeletal Disorders, 2016, 17, 39.	0.8	12
429	Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. Rheumatology, 2016, 55, 982-990.	0.9	12
430	Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. Journal of Rheumatology, 2017, 44, 1727-1733.	1.0	12
431	Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data. BMC Medicine, 2017, 15, 59.	2.3	12
432	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 31-58.	0.3	12

#	Article	IF	Citations
433	Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data. Annals of the Rheumatic Diseases, 2020, 79, 529-535.	0.5	12
434	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis and Rheumatology, 2022, 74, 1464-1473.	2.9	12
435	Underlying diagnosis predicts patient-reported outcomes after revision total knee arthroplasty. Rheumatology, 2014, 53, 361-366.	0.9	11
436	A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. Journal of Clinical Rheumatology, 2015, 21, 411-418.	0.5	11
437	Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212094.	0.5	11
438	Gout and comorbidity: a nominal group study of people with gout. Arthritis Research and Therapy, 2017, 19, 204.	1.6	11
439	Gout and the risk of age-related macular degeneration in the elderly. PLoS ONE, 2018, 13, e0199562.	1.1	11
440	Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2019, 322, 309.	3.8	11
441	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	1.0	11
442	Lupus is associated with poorer outcomes after primary total hip arthroplasty. Lupus, 2019, 28, 834-842.	0.8	11
443	Is there a role for cherries in the management of gout?. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1984701.	1.2	11
444	Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. Journal of Rheumatology, 2020, 47, 449-460.	1.0	11
445	Age, race, comorbidity, and insurance payer type are associated with outcomes after total ankle arthroplasty. Clinical Rheumatology, 2020, 39, 881-890.	1.0	11
446	Trends in Hospitalizations for Alcohol Use Disorder in the US From 1998 to 2016. JAMA Network Open, 2020, 3, e2016580.	2.8	11
447	Patient Perceptions of Gout Management Goals. Journal of Clinical Rheumatology, 2020, 26, 129-133.	0.5	11
448	Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout. Journal of Rheumatology, 2021, 48, 293-298.	1.0	11
449	Towards development of core domain sets for short term and long term studies of calcium pyrophosphate crystal deposition (CPPD) disease: A framework paper by the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 946-950.	1.6	11
450	Genetic correlations between traits associated with hyperuricemia, gout, and comorbidities. European Journal of Human Genetics, 2021, 29, 1438-1445.	1.4	11

#	Article	lF	CITATIONS
451	Talo-patello-scaphoid osteolysis, synovitis, and short fourth metacarpals in sisters: A new syndrome?. American Journal of Medical Genetics Part A, 2003, 121A, 118-125.	2.4	10
452	Discordance Between Self-report of Physician Diagnosis and Administrative Database Diagnosis of Arthritis and Its Predictors. Journal of Rheumatology, 2009, 36, 2000-2008.	1.0	10
453	Peptic ulcer disease and heart disease are associated with periprosthetic fractures after total hip replacement. Monthly Notices of the Royal Astronomical Society: Letters, 2012, 83, 353-359.	1.2	10
454	Mediation of smoking-associated postoperative mortality by perioperative complications in veterans undergoing elective surgery: data from Veterans Affairs Surgical Quality Improvement Program $(VASQIP)$ a \in "a cohort study. BMJ Open, 2013, 3, e002157.	0.8	10
455	A Call for Evidence-based Decision Making When Selecting Outcome Measurement Instruments for Summary of Findings Tables in Systematic Reviews: Results from an OMERACT Working Group. Journal of Rheumatology, 2015, 42, 1954-1961.	1.0	10
456	Do "Evidence-Based Recommendations―Need to Reveal the Evidence? Minimal Criteria Supporting an "Evidence Claim― Journal of Rheumatology, 2015, 42, 1737-1739.	1.0	10
457	Individualized patient decision-aid for immunosuppressive drugs in women with lupus nephritis: study protocol of a randomized, controlled trial. BMC Musculoskeletal Disorders, 2017, 18, 53.	0.8	10
458	Any sleep is a dream far away: a nominal group study assessing how gout affects sleep. Rheumatology, 2018, 57, 1925-1932.	0.9	10
459	Gout and the risk of incident depression in older adults. Psychiatry Research, 2018, 270, 842-844.	1.7	10
460	Gout and the risk of myocardial infarction in older adults: a study of Medicare recipients. Arthritis Research and Therapy, 2018, 20, 109.	1.6	10
461	Outcome domains reported in calcium pyrophosphate deposition studies: A scoping review by the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2020, 50, 719-727.	1.6	10
462	Serious Infections in Patients With Gout in the US: AÂNational Study of Incidence, Time Trends, and Outcomes. Arthritis Care and Research, 2021, 73, 898-908.	1.5	10
463	Predicting the environmental suitability for onchocerciasis in Africa as an aid to elimination planning. PLoS Neglected Tropical Diseases, 2021, 15, e0008824.	1.3	10
464	Efficacy of Long-term Effect and Repeat Intraarticular Botulinum toxin in Patients with Painful Total Joint Arthroplasty: A Retrospective Study. British Journal of Medicine and Medical Research, 2014, 4, 139-148.	0.2	10
465	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Journal of Arthroplasty, 2022, 37, 1676-1683.	1.5	10
466	Effect of Health-Related Quality of Life on Women and Men's Veterans Affairs (VA) Health Care Utilization and Mortality. Journal of General Internal Medicine, 2007, 22, 1260-1267.	1.3	9
467	Cerebrovascular Disease Is Associated with Outcomes After Total Knee Arthroplasty: A US Total Joint Registry Study. Journal of Arthroplasty, 2014, 29, 40-43.	1.5	9
468	Are there racial disparities in utilization and outcomes after total elbow arthroplasty?. Rheumatology International, 2015, 35, 1479-1487.	1.5	9

#	Article	IF	Citations
469	How often is the office visit needed? Predicting total knee arthroplasty revision risk using pain/function scores. BMC Health Services Research, 2016, 16, 429.	0.9	9
470	Renal dosing of allopurinol results in suboptimal gout care. Annals of the Rheumatic Diseases, 2017, 76, e1-e1.	0.5	9
471	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. Journal of Rheumatology, 2017, 44, 565-570.	1.0	9
472	Do outcomes reported in randomised controlled trials of joint replacement surgery fulfil the OMERACT 2.0 Filter? A review of the 2008 and 2013 literature. Systematic Reviews, 2017, 6, 106.	2.5	9
473	Maternal mortality and morbidity burden in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 47-61.	1.0	9
474	A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. Journal of Clinical Rheumatology, 2020, 26, 147-156.	0.5	9
475	Time-Trends in Hospitalizations with Cannabis use Disorder: A 17-Year U.S. National Study. Substance Abuse, 2022, 43, 408-414.	1.1	9
476	Public health measures to control tuberculosis in low-income countries: ethics and human rights considerations. International Journal of Tuberculosis and Lung Disease, 2011, 15, 19-24.	0.6	8
477	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. Journal of Rheumatology, 2015, 42, 1943-1946.	1.0	8
478	Is the Double Contour Sign Specific for Gout? Or Only for Crystal Arthritis?. Journal of Rheumatology, 2015, 42, 353-354.	1.0	8
479	Considering health equity when moving from evidence-based guideline recommendations to implementation: a case study from an upper-middle income country on the GRADE approach. Health Policy and Planning, 2017, 32, 1484-1490.	1.0	8
480	Health care utilization in patients with gout: a prospective multicenter cohort study. BMC Musculoskeletal Disorders, 2017, 18, 233.	0.8	8
481	Goals of gout treatment: a patient perspective. Clinical Rheumatology, 2018, 37, 2557-2566.	1.0	8
482	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. Journal of Rheumatology, 2019, 46, 1053-1058.	1.0	8
483	Total knee arthroplasty outcomes in lupus: a study using the US National Inpatient Sample. Rheumatology, 2019, 58, 2130-2136.	0.9	8
484	Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase. Rheumatology, 2019, 58, 1422-1431.	0.9	8
485	Gout and sexual function: patient perspective of how gout affects personal relationships and intimacy. BMC Rheumatology, 2019, 3, 8.	0.6	8
486	Outcome domains reported by patients, caregivers, healthcare professionals and stakeholders for calcium pyrophosphate deposition (CPPD): A content analysis based on semi-structured qualitative interviews from the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 650-654.	1.6	8

#	Article	IF	Citations
487	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. Seminars in Arthritis and Rheumatism, 2021, 51, 1108-1112.	1.6	8
488	Telemedicine Including Video-Based Visits in Rheumatology in COVID-19 Pandemic: Not Yet Ideal. Journal of Clinical Rheumatology, 2022, 28, e292-e293.	0.5	8
489	Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. PLoS ONE, 2015, 10, e0135805.	1.1	8
490	Perioperative assessment of muscle inflammation susceptibility in patients with end-stage osteoarthritis. Journal of Applied Physiology, 2022, 132, 984-994.	1.2	8
491	A national survey of Veterans Affairs Rheumatologists for relevance of quality of care indicators for Gout management. Arthritis Care and Research, 2010, 62, 1306-1311.	1.5	7
492	Emerging therapies for gout. Expert Opinion on Emerging Drugs, 2012, 17, 511-518.	1.0	7
493	Folic Acid Supplementation for Rheumatoid Arthritis Patients on Methotrexate: The Good Gets Better. , 2013, , ED000063.		7
494	Exercise therapy following surgical rotator cuff repair. The Cochrane Library, 2015, , .	1.5	7
495	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. Journal of Rheumatology, 2015, 42, 1934-1942.	1.0	7
496	Patient perspectives in gout: a review. Current Opinion in Rheumatology, 2019, 31, 159-166.	2.0	7
497	Allopurinol adherence and its predictors in gout: a national cohort study in US veterans. Lancet Rheumatology, The, 2020, 2, e281-e291.	2.2	7
498	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. Seminars in Arthritis and Rheumatism, 2021, 51, 601-606.	1.6	7
499	Applying evidence-based methods to the development and use of adverse outcome pathways. ALTEX: Alternatives To Animal Experimentation, 2021, 38, 336-347.	0.9	7
500	Belimumab for systemic lupus erythematosus. The Cochrane Library, 0, , .	1.5	6
501	Including Health Equity Considerations in Development of Instruments for Rheumatology Research: An Introduction to a Novel OMERACT Paradigm. Journal of Rheumatology, 2014, 41, 150-152.	1.0	6
502	Does <i>T'ai Chi</i> Gait Reduce External Knee Adduction Moment?. Journal of Alternative and Complementary Medicine, 2016, 22, 818-823.	2.1	6
503	Does rural residence impact total ankle arthroplasty utilization and outcomes?. Clinical Rheumatology, 2016, 35, 381-386.	1.0	6
504	The OMERACT First-time Participant Program: Fresh Eye from the New Guys. Journal of Rheumatology, 2017, 44, 1560-1563.	1.0	6

#	Article	IF	CITATIONS
505	Patient-Reported Outcomes Can Be Used to Streamline Post-Total Hip Arthroplasty Follow-Up to High-Risk Patients. Journal of Arthroplasty, 2017, 32, 3319-3321.	1.5	6
506	Allopurinol and the risk of incident peripheral arterial disease in the elderly: a US Medicare claims data study. Rheumatology, 2018, 57, 451-461.	0.9	6
507	Patient Perspectives on Gout and Gout Treatments: A Patient Panel Discussion That Informed the 2020 American College of Rheumatology Treatment Guideline. ACR Open Rheumatology, 2020, 2, 725-733.	0.9	6
508	Patient, physiotherapist and surgeon endorsement of the core domain set for total hip and total knee replacement in Germany: a study protocol for an OMERACT initiative. BMJ Open, 2020, 10, e035207.	0.8	6
509	When Has a Knee or Hip Replacement Failed? A Patient Perspective. Journal of Rheumatology, 2021, 48, 447-453.	1.0	6
510	Epidemiology and Outcomes of Alcohol Use Hospitalizations in People With Gout, Rheumatoid Arthritis, Fibromyalgia, Osteoarthritis, or Low Back Pain. Journal of Clinical Rheumatology, 2022, 28, e375-e380.	0.5	6
511	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout. RMD Open, 2021, 7, e001623.	1.8	6
512	Reply. Arthritis Care and Research, 2013, 65, 832-833.	1.5	5
513	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. BMJ Open, 2016, 6, e012026.	0.8	5
514	Chasing crystals out of the body: will treat to serum urate target for gout help us get there?. Annals of the Rheumatic Diseases, 2017, 76, 629-631.	0.5	5
515	Outcome Measures Used in Arthroplasty Trials: Systematic Review of the 2008 and 2013 Literature. Journal of Rheumatology, 2017, 44, 1277-1287.	1.0	5
516	Considering health equity when moving from evidence-based guideline recommendations to implementation: a case study from an uppermiddle income country on the GRADE approach. Health Policy and Planning, 2017, 32, 1492-1492.	1.0	5
517	Taking an Interdisciplinary Approach to Understanding and Improving Medication Adherence. Journal of General Internal Medicine, 2018, 33, 136-138.	1.3	5
518	Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. Journal of Rheumatology, 2019, 46, 1202-1206.	1.0	5
519	Gout and chronic pain in older adults: a Medicare claims study. Clinical Rheumatology, 2019, 38, 1953-1960.	1.0	5
520	Which factors predict discordance between a patient and physician on a gout flare?. Rheumatology, 2021, 60, 773-779.	0.9	5
521	Hospitalized Infections in People With Osteoarthritis: A National US Study. Journal of Rheumatology, 2021, 48, 933-939.	1.0	5
522	Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group. Seminars in Arthritis and Rheumatism, 2021, 51, 655-660.	1.6	5

#	Article	IF	Citations
523	Time trends in in-hospital mortality reduction in vasculitis vs. non-vasculitis hospitalisations vary by patient sex and age. Joint Bone Spine, 2021, 88, 105141.	0.8	5
524	Gout is associated with increased healthcare utilization after knee arthroplasty. Annals of the Rheumatic Diseases, 2019, 78, 1146-1148.	0.5	5
525	SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout. BMC Medicine, 2021, 19, 265.	2.3	5
526	Prognostic significance of baseline fatigue for overall survival: A patient-level meta-analysis of 43 oncology clinical trials with 3915 patients. Trends in Cancer Research, 2017, 12, 97-110.	1.6	5
527	Telemedicine Use During the COVID-19 Pandemic by Resilient Rheumatology Providers: A National Veterans Affairs Follow-up Survey. Journal of Rheumatology, 2022, 49, 424-431.	1.0	5
528	Ciprofloxacin-Related Acute Peripheral Neuropathy in a Patient With Lupus Nephritis. Journal of Clinical Rheumatology, 2002, 8, 143-146.	0.5	4
529	Can racial disparities in optimal gout treatment be reduced? evidence from a randomized trial. BMC Medicine, 2012, 10, 15.	2.3	4
530	OP0071â€Risk of Cancer, Serious Lung Infections and Death with Biologics: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials (RCTS). Annals of the Rheumatic Diseases, 2013, 72, A74.2-A74.	0.5	4
531	OMERACT 11: International Consensus Conference on Outcome Measures in Rheumatology. Journal of Rheumatology, 2014, 41, 145-149.	1.0	4
532	Acquired supravalvular pulmonary stenosis due to extrinsic compression by a mediastinal dermoid cyst. European Journal of Cardio-thoracic Surgery, 2014, 45, 576-578.	0.6	4
533	Total joint replacement surgery for knee osteoarthritis and other non-traumatic diseases: a network meta-analysis. The Cochrane Library, 2015, , .	1.5	4
534	Towards Consensus on the Reporting of Core Outcome Domains in Total Joint Replacement Clinical Trials: The Derivation of the Preliminary Core Outcome Domain Set. Journal of Arthritis, 2016, 05, .	0.3	4
535	Do pessimists report worse outcomes after total hip arthroplasty?. BMC Musculoskeletal Disorders, 2016, 17, 203.	0.8	4
536	Serum urate gene associations with incident gout, measured in the Framingham Heart Study, are modified by renal disease and not by body mass index. Rheumatology International, 2016, 36, 263-270.	1.5	4
537	Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis. The Cochrane Library, 0, , .	1.5	4
538	Gout and hearing impairment in the elderly: a retrospective cohort study using the US Medicare claims data. BMJ Open, 2018, 8, e022854.	0.8	4
539	The risk of Sjogren's syndrome in the older adults with gout: A medicare claims study. Joint Bone Spine, 2019, 86, 615-619.	0.8	4
540	Sjogren's syndrome is associated with higher rate of non-home discharge after primary hip arthroplasty and higher transfusion rates after primary hip or knee arthroplasty: a U.S. cohort study. BMC Musculoskeletal Disorders, 2020, 21, 492.	0.8	4

#	Article	IF	CITATIONS
541	Epidemiology, Timeâ€trends and Outcomes of Serious Infections in Patients with Vasculitis: A 19â€year National Study. Arthritis Care and Research, 2020, 73, 1544-1551.	1.5	4
542	Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA). Joint Bone Spine, 2020, 87, 307-313.	0.8	4
543	Acute kidney injury after primary total hip arthroplasty: a risk multiplier for complication, mortality, and healthcare utilization. Arthritis Research and Therapy, 2020, 22, 31.	1.6	4
544	Serious infections in people with systemic sclerosis: a national US study. Arthritis Research and Therapy, 2020, 22, 163.	1.6	4
545	How Systemic Sclerosis Affects Healthcare Use and Complication Rates after Total Hip Arthroplasty. Journal of Rheumatology, 2020, 47, 1218-1223.	1.0	4
546	Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice. Clinical Rheumatology, 2021, 40, 693-700.	1.0	4
547	Benefit–risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain, 2022, 163, 1006-1018.	2.0	4
548	Recent health-related quality of life, but not change, predicted mortality and healthcare utilization. Journal of Clinical Epidemiology, 2021, 140, 13-21.	2.4	4
549	Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension. Hypertension, 2022, 79, 775-784.	1.3	4
550	Contributions of OMERACT to rheumatic disease research. Arthritis and Rheumatism, 2007, 57, 186-186.	6.7	3
551	Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate. Cmaj, 2013, 185, 793-795.	0.9	3
552	Methotrexate use and liver disease - a causal relationship?. British Journal of Dermatology, 2014, 171, 6-7.	1.4	3
553	The OMERACT First-time Participant ("Newbieâ€) Program: Initial Assessment and Lessons Learned. Journal of Rheumatology, 2015, 42, 1976-1981.	1.0	3
554	Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?. Annals of the Rheumatic Diseases, 2017, 76, 779-781.	0.5	3
555	EULAR gout treatment guidelines by Richette et al.: uric acid and neurocognition. Annals of the Rheumatic Diseases, 2018, 77, e20-e20.	0.5	3
556	Response to: †Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults' by Lee and Song. Annals of the Rheumatic Diseases, 2018, 77, e74-e74.	0.5	3
557	Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain. JAMA - Journal of the American Medical Association, 2018, 320, 508.	3.8	3
558	Self-reported sleep quality and sleep disorders in people with physician-diagnosed gout: an Internet cross-sectional survey. Arthritis Research and Therapy, 2019, 21, 36.	1.6	3

#	Article	IF	CITATIONS
559	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3×3 Methodology Applied to Two Active Comparator Trials. Arthritis Care and Research, 2019, 71, 319-322.	1.5	3
560	Systemic sclerosis is associated with knee arthroplasty outcomes: a National US study. Clinical Rheumatology, 2020, 39, 85-92.	1.0	3
561	Serious infections in people with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA): a time-trend national US study. Clinical Rheumatology, 2020, 39, 3427-3438.	1.0	3
562	Juvenile idiopathic arthritis is associated with higher healthcare utilization after total knee or hip replacement. Scandinavian Journal of Rheumatology, 2021, 50, 34-39.	0.6	3
563	Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis. Joint Bone Spine, 2021, 88, 105053.	0.8	3
564	How do dietary interventions affect serum urate and gout?. Nature Reviews Rheumatology, 2021, 17, 191-192.	3.5	3
565	Implementing the DEcision-Aid for Lupus (IDEAL): study protocol of a multi-site implementation trial with observational, case study design. Implementation Science Communications, 2021, 2, 30.	0.8	3
566	Time-trends in cocaine, hallucinogen, amphetamine, and sedative/anxiolytic/hypnotic use disorder hospitalizations in rheumatic diseases: a national time-trends study. Clinical Rheumatology, 2021, 40, 3007-3014.	1.0	3
567	Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death. Journal of Rheumatology, 2021, 48, 1745-1753.	1.0	3
568	Osteoarthritis Progression: Mitigation and Rehabilitation Strategies. Frontiers in Rehabilitation Sciences, 2021, 2, .	0.5	3
569	Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 1378-1385.	1.6	3
570	Physician, Nurse, and Advanced Practice Provider Perspectives on the Rapid Transition to Inpatient and Outpatient Telemedicine. Telemedicine Reports, 2022, 3, 7-14.	0.5	3
571	Health Care Costs in Gout. Journal of Clinical Rheumatology, 2009, 15, 1-2.	0.5	2
572	Responsiveness differences in outcome instruments after revision hip arthroplasty: What are the implications?. BMC Musculoskeletal Disorders, 2011, 12, 107.	0.8	2
573	Total hip replacement surgery versus conservative care for hip osteoarthritis and other non-traumatic diseases. The Cochrane Library, 2013, , .	1.5	2
574	Total joint replacement surgery versus conservative care for knee osteoarthritis and other non-traumatic diseases. The Cochrane Library, 2013, , .	1.5	2
575	Editorial: Arthroplasty Outcomes Are Improving, but Why Isn't My Patient With Rheumatoid Arthritis Doing as Well?. Arthritis and Rheumatology, 2014, 66, 250-253.	2.9	2
576	Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Pediatric Rheumatology, 2014, 12, .	0.9	2

#	Article	IF	Citations
577	Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial. Clinical Rheumatology, 2017, 36, 1357-1367.	1.0	2
578	Management of Gout. Annals of Internal Medicine, 2017, 166, 855.	2.0	2
579	Gout and Hypothyroidism in the Elderly: an Observational Cohort Study Using U.S. Medicare Claims Data. Journal of General Internal Medicine, 2018, 33, 1229-1231.	1.3	2
580	Role of serum urate in neurocognitive function and dementia: new evidence contradicts old thinking. Annals of the Rheumatic Diseases, 2018, 77, 317-318.	0.5	2
581	The association of gout with incident giant cell arteritis in older adults. Joint Bone Spine, 2019, 86, 219-224.	0.8	2
582	Are the days of missed or delayed diagnosis of gout over?. Nature Reviews Rheumatology, 2019, 15, 578-580.	3.5	2
583	Gout and healthcare utilization and complications after hip arthroplasty: a cohort study using the US National Inpatient Sample (NIS). Clinical Rheumatology, 2019, 38, 1213-1216.	1.0	2
584	Factors influencing implementation of a computerized, individualized, culturally tailored lupus decision aid in lupus clinics: a qualitative semi-structured interview study. Clinical Rheumatology, 2019, 38, 2793-2801.	1.0	2
585	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. Journal of Rheumatology, 2019, 46, 1355-1359.	1.0	2
586	Patient-Centered Outcomes and Key Study Procedure Finalization in the Pilot Feasibility Gout Randomized Trial. Journal of Clinical Rheumatology, 2020, 26, 181-191.	0.5	2
587	Acute kidney injury is associated with increased healthcare utilization, complications, and mortality after primary total knee arthroplasty. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2090872.	1.2	2
588	Comment on: Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis. Rheumatology, 2021, 60, e222-e224.	0.9	2
589	Factors associated with healthcare utilization and mortality in alcohol use disorder hospitalization. Drug and Alcohol Dependence, 2021, 222, 108653.	1.6	2
590	Epidemiology of hospitalizations with cocaine use disorder: A 17-year U.S. national study. Journal of Psychiatric Research, 2021, 144, 32-36.	1.5	2
591	Medicaid Payer Status, Higher Comorbidity, and Low Income Are Associated With Poorer Outcomes After Total Elbow Arthroplasty. Journal of Clinical Rheumatology, 2021, 27, 311-316.	0.5	2
592	Infection versus cardiovascular disease as leading causes of hospitalisations and associated mortality in vasculitis in the U.S.: a national study. Clinical and Experimental Rheumatology, 2021, 39, 56-61.	0.4	2
593	Change in serum urate level with urate-lowering therapy initiation associates in the immediate term with patient-reported outcomes in people with gout. Seminars in Arthritis and Rheumatism, 2022, 56, 152057.	1.6	2
594	Chronic Constrictive Calcific Pericarditis. Asian Cardiovascular and Thoracic Annals, 2008, 16, 432-433.	0.2	1

#	Article	IF	Citations
595	ANTIDEPRESSANTS FOR PEOPLE WITH EPILEPSY AND DEPRESSION. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e3.39-e3.	0.9	1
596	Reply. Arthritis Care and Research, 2016, 68, 725-726.	1.5	1
597	Reply. Arthritis and Rheumatology, 2016, 68, 1316-1318.	2.9	1
598	The risk of polymyalgia rheumatica in older adults with gout: a Medicare claims study. Rheumatology Advances in Practice, 2018, 2, rky024.	0.3	1
599	Association of Gout With Uveitis in Older Individuals. JAMA Ophthalmology, 2018, 136, 835.	1.4	1
600	The Third Biennial 2018 OMERACT First-time Participant Program: A Qualitative and Quantitative Study. Journal of Rheumatology, 2019, 46, 1036-1040.	1.0	1
601	Polymyositis has minimal effect on primary total knee or hip arthroplasty outcomes. Clinical Rheumatology, 2020, 39, 823-830.	1.0	1
602	Treatment Guidelines in Rheumatoid Arthritisâ€"Optimizing the Best of Both Worlds. Current Treatment Options in Rheumatology, 2020, 6, 354-369.	0.6	1
603	Response to: †Correspondence to †œ Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data†by Ma <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e108-e108.	0.5	1
604	Spondyloarthritis is associated with higher healthcare utilization and complication rates after primary total knee or total hip arthroplasty. Clinical Rheumatology, 2020, 39, 2345-2353.	1.0	1
605	The changing epidemiology of inpatient gout and associated mortality: a 17-year national study. Rheumatology, 2021, 60, 462-465.	0.9	1
606	Comment on: Dual-energy computed tomography versus ultrasound, alone or combined, for the diagnosis of gout: a prospective study of accuracy: reply. Rheumatology, 2021, 60, e372-e374.	0.9	1
607	Time trends in hospitalizations with anxiolytic, sedative, or hypnotic drug use disorder: a 17-year U.S. national study. Journal of Addictive Diseases, 2022, 40, 4-11.	0.8	1
608	Organizational context and the learning and change readiness climate for implementing an evidence-based shared decision-making aid in US rheumatology clinics. Journal of Health Organization and Management, 2021, ahead-of-print, .	0.6	1
609	Management of Rheumatic Diseases During the COVID-19 Pandemic: A National Veterans Affairs Survey of Rheumatologists., 2021, 73, 998.		1
610	Declining in-hospital mortality gap between systemic lupus erythematosus (SLE) and non-SLE hospitalisations: a national study. Annals of the Rheumatic Diseases, 2021, 80, 672-675.	0.5	1
611	"l wish it had a place to go― a nominal group study of barriers to the effectiveness of non-surgical treatments for knee osteoarthritis inclusive of minority populations. Arthritis Research and Therapy, 2021, 23, 291.	1.6	1
612	Disease modification in gout: a qualitative study of gout expert rheumatologists. Rheumatology Advances in Practice, 2022, 6, rkab107.	0.3	1

#	Article	IF	CITATIONS
613	Patient empowerment among adults with arthritis: the case for emotional support. Journal of Rheumatology, 2022, , jrheum.210818.	1.0	1
614	Serious infections in Sj \tilde{A} ¶gren's syndrome patients: a national U.S. study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 47-52.	0.4	1
615	SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol. Trials, 2021, 22, 879.	0.7	1
616	HRQOL PREDICTS HEALTH CARE UTILIZATION AND MORTALITY IN VETERANS WITH ARTHRITIS Journal of Investigative Medicine, 2004, 52, S380.	0.7	0
617	REPORT ON INTRA-ARTICULAR BOTULINUM TOXIN TYPE A FOR REFRACTORY JOINT PAIN Journal of Investigative Medicine, 2004, 52, S379.	0.7	0
618	INTRA-ARTICULAR BOTULINUM A TOXIN FOR CHRONIC SHOULDER PAIN IN THE ELDERLY Journal of Investigative Medicine, 2004, 52, S380.	0.7	0
619	Antibiotics for reactive arthritis. The Cochrane Library, 2006, , .	1.5	0
620	Surgical Management of Aortic Stenosis in a Child. Medical Journal Armed Forces India, 2008, 64, 197-198.	0.3	0
621	Botulinum Toxin for Osteoarticular Pain. , 2009, , 295-307.		0
622	Effet des exercices de renforcement musculaire sur la densité minérale osseuse chez les femmes en période de préménopause. Revue Du Rhumatisme (Edition Francaise), 2009, 76, 439-447.	0.0	0
623	Extramediastinal thymolipomasâ€"challenges in diagnosis and dilemmas in approaches: a review. Indian Journal of Thoracic and Cardiovascular Surgery, 2010, 26, 255-258.	0.2	0
624	Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review. Journal of Rheumatology, 2010, 37, 682-682.	1.0	0
625	Quality of Care in Gout. , 2012, , 209-216.		0
626	Is HLAB genotyping the future of gout pharmacogenomics?. Nature Reviews Rheumatology, 2013, 9, 200-202.	3.5	0
627	Ofatumumab for rheumatoid arthritis. The Cochrane Library, 0, , .	1.5	0
628	Perioperative interventions for smoking cessation in hip and knee arthroplasty for osteoarthritis and other non-traumatic diseases. The Cochrane Library, 2013, , .	1.5	0
629	The use of botulinum neurotoxin in musculoskeletal pain and arthritis., 0,, 233-242.		0
630	Patient-Centered Outcomes Research Institute (PCORI) multisite project to develop treatment decision aids for racial/ethnic minorities with lupus nephritis. Arthritis Research and Therapy, 2014, 16, A48.	1.6	0

#	Article	IF	Citations
631	Subcutaneous or intramuscular methotrexate for rheumatoid arthritis. The Cochrane Library, 2015, , .	1.5	0
632	Consensus on the need for a hierarchical list of patient-reported pain outcomes for meta-analyses of knee osteoarthritis trials. Trials, $2015, 16, .$	0.7	0
633	Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporosis International, 2015, 26, 1971-1977.	1.3	0
634	Regional analgesia versus no regional analgesia for ambulatory hip arthroscopy in adults. The Cochrane Library, $0, , .$	1.5	0
635	Ms. A.M. Taylor, et al reply. Journal of Rheumatology, 2016, 43, 826.2-827.	1.0	0
636	Cervical cancer risk with the use of tumour necrosis factor inhibitors in rheumatoid arthritis: to worry or not to worry?. Annals of the Rheumatic Diseases, 2016, 75, 1265-1267.	0.5	0
637	Long-Term Anticoagulation for Unprovoked Pulmonary Embolism, Monitoring Sleep with an App, and Interventional Bronchoscopy for Airway Obstruction. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 330-332.	2.5	0
638	Shoulder replacement surgery for osteoarthritis and rotator cuff tear arthropathy. The Cochrane Library, 2017, , .	1.5	0
639	Weight loss for overweight patients with knee or hip osteoarthritis. The Cochrane Library, 0, , .	1.5	O
640	Response to: 'A response to Singh. "Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer?†by Valiyil and Schechter. Annals of the Rheumatic Diseases, 2018, 77, e42-e42.	0.5	0
641	Interleukin inhibitors for psoriatic arthritis. The Cochrane Library, 0, , .	1.5	0
642	AB1213â \in PATIENTSâ \in TM PERSPECTIVES OF OUTCOMES AFTER TOTAL KNEE AND TOTAL HIP ARTHROPLASTY: A NOMINAL GROUP STUDY. , 2019, , .		0
643	AB1317â€WHAT IS A TOTAL KNEE OR TOTAL HIP ARTHROPLASTY FAILURE? A PATIENT PERSPECTIVE USING NOMINAL GROUPS. , 2019, , .		O
644	Challenges of Practicing Rheumatology in a Government Setting. Rheumatic Disease Clinics of North America, 2019, 45, 39-51.	0.8	0
645	Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?. Annals of the Rheumatic Diseases, 2019, 78, 153-154.	0.5	O
646	Response to Letter to the Editor on "Assessment of a Satisfaction Measure for Use After Primary Total Joint Arthroplasty― Journal of Arthroplasty, 2020, 35, 3418-3419.	1.5	0
647	Response to:  Confunding by indication and ethnicity difference? Comment on  Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu <i>et al</i> Annals of the Rheumatic Diseases, 2022, 81, e123-e123.	0.5	O
648	Response to: â€~Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e125-e125.	0.5	O

#	Article	IF	CITATIONS
649	Traitement anti-TNF ou non anti-TNF dans la polyarthrite rhumatoÃ ⁻ de activeÂ: facteurs déterminant le choix des patients. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 49-55.	0.0	0
650	In-hospital mortality reduction in systemic lupus erythematosus over 2 decades varied by patient sex and age. Clinical Rheumatology, 2021, 40, 1201-1203.	1.0	0
651	Epidemiology of cardiac or orthopedic procedures in gout versus rheumatoid arthritis: a national time-trends study. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2097391.	1.2	0
652	Driving Impairment Following Vaporization of Cannabis. JAMA - Journal of the American Medical Association, 2021, 325, 1226.	3.8	0
653	Epidemiology of hospitalizations with hallucinogen use disorder: a 17-year U.S. National study. Journal of Addictive Diseases, 2021, 39, 1-8.	0.8	0
654	OMERACT 2020: A virtual (R)evolution. Seminars in Arthritis and Rheumatism, 2021, 51, 588-592.	1.6	0
655	Letter to the editor: Cocaine use and cocaine use disorder: Revisiting epidemiology and clinical impact. Journal of Psychiatric Research, 2021, 143, 467-468.	1.5	O
656	Cardiovascular safety of febuxostat. Lancet, The, 2021, 398, 955.	6.3	0
657	Prendre un comprim \tilde{A} © ou me faire une injection \hat{A} ? Point de vue des patients quant au choix des traitements de fond (DMARD) dans la polyarthrite rhumato \tilde{A} de (PR). Revue Du Rhumatisme (Edition) Tj ETQq1	1 00 7.8 4314	4 r g BT /Overl
658	Epidemiology of hospitalizations with amphetamine use disorder: A 17-year U.S. national cross-sectional study. Asian Journal of Psychiatry, 2021, 65, 102849.	0.9	0
659	Editorial: Current Concepts in Arthroplasty §. The Open Orthopaedics Journal, 2011, 5, 78-79.	0.1	0
660	Biologic pathways, candidate genes, and molecular markers associated with quality-of-life domains Journal of Clinical Oncology, 2014, 32, 1561-1561.	0.8	0
661	PROMs for Gouty Arthritis., 2016,, 225-247.		O
662	Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance). International Journal of Statistics in Medical Research, 2018, 7, 137-146.	0.5	0
663	Abstract P162: Gout and Risk for Incident Heart Failure, Coronary Heart Disease and Stroke: The REasons for Geographic And Racial Differences in Stroke (REGARDS) Study. Circulation, 2019, 139, .	1.6	O
664	Declining in-hospital mortality in vasculitis: A 17-year US national study. , 2021, 8, 232-234.		0
665	Identifying physician-perceived barriers to a pragmatic treatment trial in rheumatoid arthritis., 2022, 9, 132-138.		O
666	Freedom of speech and public interest, not allegiance, should underpin science advisement to government. South African Medical Journal, 2020, 110, 578-580.	0.2	0

#	Article	IF	CITATIONS
667	Infection versus cardiovascular disease as leading causes of hospitalisations and associated mortality in vasculitis in the U.S.: a national study. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 56-61.	0.4	O
668	Title is missing!. , 2020, 15, e0229174.		0
669	Title is missing!. , 2020, 15, e0229174.		O
670	Title is missing!. , 2020, 15, e0229174.		0
671	Title is missing!. , 2020, 15, e0229174.		0
672	Gout management and outcomes during established COVID-19 pandemic in 2020–2021: a cross-sectional Internet survey. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210963.	1.2	0